The US Food and Drug Administration (FDA) has approved sotatercept (Winrevair, Merck), for the treatment of adults with pulmonary arterial hypertension (PAH), World Health Organization (WHO) Group 1, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback